Beijing Strong Biotechnologies Inc(300406) february 25 announced that the company signed the investment agreement on Wuhan Huihai Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as “Huihai pharmaceutical”) with Wuhan Huihai Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as “Huihai pharmaceutical”) and its shareholders Xia Zhihui and Wang Ying, and agreed to transfer 75% equity of Huihai pharmaceutical jointly held by Xia Zhihui and Wang Ying with RMB 4 million. The capital source of this transaction is the company’s own funds.
The announcement shows that Huihai pharmaceutical is mainly engaged in in vitro diagnosis, and its core business is the R & D and registration of covid-19 antigen detection products. Based on Huihai pharmaceutical’s leadership and professionalism in covid-19 antigen detection, this acquisition can accelerate the registration of Beijing Strong Biotechnologies Inc(300406) covid-19 antigen detection products, expand the company’s product line, further improve the competitiveness and comprehensive strength of the company’s detection business, and is of positive significance to the company’s performance growth.
Beijing Strong Biotechnologies Inc(300406) is a national high-tech enterprise mainly engaged in the R & D, production and sales of in vitro diagnostic products, with a series of in vitro diagnostic products developed synchronously with the world. Previously, Beijing Strong Biotechnologies Inc(300406) has said on the investor interaction platform that the company has obtained CE certification of total anti and medical version antigen cards, and New Coronavirus antibody detection kit (latex immunoturbidimetry) has been sold overseas. At present, the company’s overseas sales prospects are very optimistic and the orders are in good condition. With the improvement of overseas vaccination rate and the expansion of vaccination population, there is a large potential market space for antibody testing in the future. In 202219, the company will continue to actively expand the global sales of vid and its distributors.
